A recent study published in the International Journal of Clinical Oncology researchers from Kinki University Japan the effectiveness of chemotherapy combination cisplatin and Pemetrexed as a second line treatment for malignant pleural mesothelioma evaluated.
The study titled reprocessing the recurrent malignant pleural mesothelioma cisplatin / Pemetrexed, analyses four patients who had received already cisplatin and Pemetrexed as first-line treatment option.
The combination of cisplatin and Pemetrexed is currently the most common malignant mesothelioma treatment approach. It is however no preferred treatment for patients who experience recurring mesothelioma.
Reprocessing with cisplatin and Pemetrexed underwent four patients during the study. An objective answer to the treatment had two of the patients during any signs of disease progression for months 6.4 and receive 11.4. The other two patients experienced stable disease for months 5.0 and 7.8.
After receiving cisplatin and Pemetrexed as second-line treatment approach, a partial answer with a progression of the disease of 5.0 and 8.2 months experienced two patients who first reached an objective answer. The other two patients experienced disease progression in 1.0 and 1.4 months after receiving the reprocessing.
According to H. Hayashi and colleagues was "reprocessing with cisplatin plus Pemetrexed generally well tolerated." "Reprocessing with cisplatin and Pemetrexed is a potential therapeutic option for certain patients with recurrent Haemangioendothelioma malignant pleural mesothelioma, possibly including those to show tumor regression with a duration to the progression of six months or more after initial chemotherapy."
The researchers also said that further research is needed to further evaluate of the effectiveness of cisplatin and Pemetrexed as second line reprocessing option for mesothelioma patients.
Learn more about Mesothelioma can be found through the mesothelioma Center.
This entry was posted on Monday, November 29th, 2009 at 4: 20 pm and is filed under treatment mesothelioma, mesothelioma, mesothelioma research. You can follow RSS feed any responses to this entry through the. You are currently closed trackback responses, but from your own site.
